<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2485">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794829</url>
  </required_header>
  <id_info>
    <org_study_id>10000256</org_study_id>
    <secondary_id>000256-I</secondary_id>
    <nct_id>NCT04794829</nct_id>
  </id_info>
  <brief_title>Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination</brief_title>
  <official_title>Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title:&#xD;
&#xD;
      Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults&#xD;
      after Vaccination&#xD;
&#xD;
      Study Description:&#xD;
&#xD;
      Yearly influenza vaccination is necessary due to short-lasting influenza immunity and&#xD;
      changing strains of circulating influenza. With limited effectiveness of yearly influenza&#xD;
      vaccines and the ongoing potential for an influenza pandemic, there is a need for a better&#xD;
      understanding of influenza immunity to develop improved vaccines. Severe acute respiratory&#xD;
      syndrome coronavirus 2 (SARS CoV-2) vaccines have been developed in response to the&#xD;
      coronavirus disease 2019 (COVID-19) pandemic. There is a critical need to also understand the&#xD;
      changes in long-term immunity in those who receive a SARS CoV-2 vaccine to develop improved&#xD;
      vaccines. We will investigate the changes in long-term immunity of NIH workers after&#xD;
      vaccination with influenza and/or SARS-CoV-2 and throughout the following year via blood and&#xD;
      nasal sampling.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
      Characterize the systemic anti-influenza humoral immune response to vaccination over 1 year.&#xD;
&#xD;
      Characterize the systemic anti-SARS-CoV-2 humoral immune response to vaccination over 1 year.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      Characterize the nasal mucosal anti-influenza humoral immune response to vaccination over 1&#xD;
      year.&#xD;
&#xD;
      Characterize the nasal mucosal anti-SARS-CoV-2 humoral immune response to vaccination over 1&#xD;
      year.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary Endpoints:&#xD;
&#xD;
        1. Systemic anti-influenza antibodies as measured by:&#xD;
&#xD;
             1. Hemagglutination inhibition (HAI) antibody titers&#xD;
&#xD;
             2. Neuraminidase inhibition (NAI) antibody titers&#xD;
&#xD;
             3. Anti-Hemagglutinin (HA) head antibody quantitative enzyme linked immunosorbent&#xD;
                assay (ELISA) (immunoglobulin [Ig] M, IgG, IgA)&#xD;
&#xD;
             4. Anti-HA stalk antibody quantitative ELISA (IgM, IgG, IgA)&#xD;
&#xD;
             5. Anti-Neuraminidase (NA) antibody quantitative ELISA (IgM, IgG, IgA)&#xD;
&#xD;
        2. Systemic anti-SARS-CoV-2 antibodies as measured by:&#xD;
&#xD;
             1. Anti-SARS-CoV-2 spike antibody quantitative ELISA (IgM, IgG, IgA)&#xD;
&#xD;
             2. Anti-SARS-CoV-2 receptor binding domain (RBD) antibody quantitative ELISA (IgM,&#xD;
                IgG, IgA)&#xD;
&#xD;
      Secondary Endpoints:&#xD;
&#xD;
        1. Mucosal anti-influenza antibodies from nasal samples as measured by:&#xD;
&#xD;
             1. Anti-HA head antibody quantitative ELISA (IgA, IgG)&#xD;
&#xD;
             2. Anti-HA stalk antibody quantitative ELISA (IgA, IgG)&#xD;
&#xD;
             3. Anti-NA antibody quantitative ELISA (IgA, IgG)&#xD;
&#xD;
        2. Mucosal anti-SARS-CoV-2 antibodies from nasal samples as measured by:&#xD;
&#xD;
             1. Anti-SARS-CoV-2 spike antibody quantitative ELISA (IgA, IgG)&#xD;
&#xD;
             2. Anti-SARS-CoV-2 RBD antibody quantitative ELISA (IgA, IgG)&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      NIH staff (N=100) who are 18 years and older. NIH staff may include employees and&#xD;
      contractors, fellows and volunteers. Accrual ceiling N=150.&#xD;
&#xD;
      Description of Sites/Facilities Enrolling Participants:&#xD;
&#xD;
      Participants will be enrolled at the NIH Clinical Center (CC).&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      5 years&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title:&#xD;
&#xD;
      Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults&#xD;
      after Vaccination&#xD;
&#xD;
      Study Description:&#xD;
&#xD;
      Yearly influenza vaccination is necessary due to short-lasting influenza immunity and&#xD;
      changing strains of circulating influenza. With limited effectiveness of yearly influenza&#xD;
      vaccines and the ongoing potential for an influenza pandemic, there is a need for a better&#xD;
      understanding of influenza immunity to develop improved vaccines. Severe acute respiratory&#xD;
      syndrome coronavirus 2 (SARS CoV-2) vaccines have been developed in response to the&#xD;
      coronavirus disease 2019 (COVID-19) pandemic. There is a critical need to also understand the&#xD;
      changes in long-term immunity in those who receive a SARS CoV-2 vaccine to develop improved&#xD;
      vaccines. We will investigate the changes in long-term immunity of NIH workers after&#xD;
      vaccination with influenza and/or SARS-CoV-2 and throughout the following year via blood and&#xD;
      nasal sampling.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
      Characterize the systemic anti-influenza humoral immune response to vaccination over 1 year.&#xD;
&#xD;
      Characterize the systemic anti-SARS-CoV-2 humoral immune response to vaccination over 1 year.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      Characterize the nasal mucosal anti-influenza humoral immune response to vaccination over 1&#xD;
      year.&#xD;
&#xD;
      Characterize the nasal mucosal anti-SARS-CoV-2 humoral immune response to vaccination over 1&#xD;
      year.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary Endpoints:&#xD;
&#xD;
        1. Systemic anti-influenza antibodies as measured by:&#xD;
&#xD;
             1. Hemagglutination inhibition (HAI) antibody titers&#xD;
&#xD;
             2. Neuraminidase inhibition (NAI) antibody titers&#xD;
&#xD;
             3. Anti-Hemagglutinin (HA) head antibody quantitative enzyme linked immunosorbent&#xD;
                assay (ELISA) (immunoglobulin [Ig] M, IgG, IgA)&#xD;
&#xD;
             4. Anti-HA stalk antibody quantitative ELISA (IgM, IgG, IgA)&#xD;
&#xD;
             5. Anti-Neuraminidase (NA) antibody quantitative ELISA (IgM, IgG, IgA)&#xD;
&#xD;
        2. Systemic anti-SARS-CoV-2 antibodies as measured by:&#xD;
&#xD;
             1. Anti-SARS-CoV-2 spike antibody quantitative ELISA (IgM, IgG, IgA)&#xD;
&#xD;
             2. Anti-SARS-CoV-2 receptor binding domain (RBD) antibody quantitative ELISA (IgM,&#xD;
                IgG, IgA)&#xD;
&#xD;
      Secondary Endpoints:&#xD;
&#xD;
        1. Mucosal anti-influenza antibodies from nasal samples as measured by:&#xD;
&#xD;
             1. Anti-HA head antibody quantitative ELISA (IgA, IgG)&#xD;
&#xD;
             2. Anti-HA stalk antibody quantitative ELISA (IgA, IgG)&#xD;
&#xD;
             3. Anti-NA antibody quantitative ELISA (IgA, IgG)&#xD;
&#xD;
        2. Mucosal anti-SARS-CoV-2 antibodies from nasal samples as measured by:&#xD;
&#xD;
             1. Anti-SARS-CoV-2 spike antibody quantitative ELISA (IgA, IgG)&#xD;
&#xD;
             2. Anti-SARS-CoV-2 RBD antibody quantitative ELISA (IgA, IgG)&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      NIH staff (N=100) who are 18 years and older. NIH staff may include employees and&#xD;
      contractors, fellows and volunteers. Accrual ceiling N=150.&#xD;
&#xD;
      Description of Sites/Facilities Enrolling Participants:&#xD;
&#xD;
      Participants will be enrolled at the NIH Clinical Center (CC).&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      5 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 19, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic anti-influenza antibodies</measure>
    <time_frame>One year</time_frame>
    <description>Characterize the systemic anti-influenza humoral immune response to vaccination over 1 year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic anti-SARS-CoV-2 antibodies</measure>
    <time_frame>One year</time_frame>
    <description>Characterize the systemic anti-SARS-CoV-2 humoral immune response to vaccination over 1 year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mucosal anti-influenza antibodies from nasal samples</measure>
    <time_frame>One year</time_frame>
    <description>Characterize the nasal mucosal anti-influenza humoral immune response to vaccination over 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal anti-SARS-CoV-2 antibodies from nasal samples</measure>
    <time_frame>One year</time_frame>
    <description>Characterize the nasal mucosal anti-SARS-CoV-2 humoral immune response to vaccination over 1 year.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Influenza</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>NIH staff</arm_group_label>
    <description>NIH staff who are 18 years and older. NIH staff may include employees and contractors, fellows and volunteers.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        NIH staff may include employees and contractors, fellows and volunteers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        In order to be eligible to participate in this study, an individual must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          1. NIH staff members, at the time of enrollment.&#xD;
&#xD;
          2. Able to provide informed consent.&#xD;
&#xD;
          3. &gt;=18 years of age.&#xD;
&#xD;
          4. Planning to receive the current influenza season s vaccine and/or an FDA-authorized or&#xD;
             approved SARS-CoV-2 vaccine.&#xD;
&#xD;
          5. Willing and able to undergo blood draws or home blood samplings and nasal sampling&#xD;
             procedures.&#xD;
&#xD;
          6. Willing and able to undergo at least one blood draw and one nasal sampling prior to&#xD;
             receiving vaccine.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
          1. Already received the current season s influenza vaccine and does not plan to receive&#xD;
             an FDA-authorized or approved SARS CoV-2 vaccine.&#xD;
&#xD;
          2. Already received an FDA-authorized or approved SARS-CoV-2 vaccine and does not plan to&#xD;
             receive the current season s influenza vaccine.&#xD;
&#xD;
          3. Not willing to receive the current influenza season's vaccine and not willing to&#xD;
             receive an FDA-authorized or approved SARS-CoV-2 vaccine.&#xD;
&#xD;
          4. Any condition that, in the opinion of the investigator, contraindicates participation&#xD;
             in this study.&#xD;
&#xD;
        Co-enrollment guidelines: Participants may be co-enrolled in other studies; however, study&#xD;
        staff should be notified of co-enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holly A Baus, R.N.</last_name>
    <phone>(301) 761-6800</phone>
    <email>holly.baus@nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_000256-I.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Black CL, Yue X, Ball SW, Fink RV, de Perio MA, Laney AS, Williams WW, Graitcer SB, Fiebelkorn AP, Lu PJ, Devlin R. Influenza Vaccination Coverage Among Health Care Personnel - United States, 2017-18 Influenza Season. MMWR Morb Mortal Wkly Rep. 2018 Sep 28;67(38):1050-1054. doi: 10.15585/mmwr.mm6738a2.</citation>
    <PMID>30260944</PMID>
  </reference>
  <reference>
    <citation>Ferdinands JM, Fry AM, Reynolds S, Petrie J, Flannery B, Jackson ML, Belongia EA. Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. Clin Infect Dis. 2017 Mar 1;64(5):544-550. doi: 10.1093/cid/ciw816. Epub 2016 Dec 29.</citation>
    <PMID>28039340</PMID>
  </reference>
  <reference>
    <citation>Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, Petrie JG, Lofthus G, Meece JK, Williams JV, Berman L, Breese Hall C, Monto AS, Griffin MR, Belongia E, Shay DK; US Flu-VE Network. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis. 2012 Oct;55(7):951-9. Epub 2012 Jul 25.</citation>
    <PMID>22843783</PMID>
  </reference>
  <verification_date>March 31, 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flu</keyword>
  <keyword>Antibody</keyword>
  <keyword>Immunization</keyword>
  <keyword>Pandemic</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

